MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML

Yin Xiong; Zejuan Li; Min Ji; Aik Choon Tan; Judson Bemis; Jove Victor Tse; Gang Huang; Jino Park; Chunyan Ji; Jianjun Chen; Lynne T. Bemis; Kevin D. Bunting; William Tse

doi:10.1111/j.1365-2141.2011.08662.x

MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML

Yin Xiong, Zejuan Li, Min Ji, Aik Choon Tan, Judson Bemis, Jove Victor Tse, Gang Huang, Jino Park, Chunyan Ji, Jianjun Chen, Lynne T. Bemis, Kevin D. Bunting, William Tse

Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

MLLT11, an MLL fusion partner, is a poor prognostic biomarker for paediatric acute myeloid leukaemia (AML), adult normal cytogenetics AML, and adult myelodysplastic syndrome. MLLT11 is highly regulated during haematopoietic progenitor differentiation and development but its regulatory mechanisms have not been defined. In this study, we demonstrate by transfection experiments that MIR29B directly regulates MLLT11 expression in vitro. MIR29B expression level was also inversely related to MLLT11 expression in a cohort of 56 AML patients (P<0·05). AML patients with low MIR29B/elevated MLLT11 expression had poor overall survival (P=0·038). Therefore, MIR29B may be a potential prognostic biomarker for AML patients.

Original language	English (US)
Pages (from-to)	753-757
Number of pages	5
Journal	British journal of haematology
Volume	153
Issue number	6
DOIs	https://doi.org/10.1111/j.1365-2141.2011.08662.x
State	Published - Jun 2011

Keywords

AML prognostic marker
AML survival
MIR29
MLL fusion gene
MLLT11

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1111/j.1365-2141.2011.08662.x

OpenUrl availability

Full text

Cite this

Xiong, Y., Li, Z., Ji, M., Tan, A. C., Bemis, J., Tse, J. V., Huang, G., Park, J., Ji, C., Chen, J., Bemis, L. T., Bunting, K. D., & Tse, W. (2011). MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML. British journal of haematology, 153(6), 753-757. https://doi.org/10.1111/j.1365-2141.2011.08662.x

Xiong, Y, Li, Z, Ji, M, Tan, AC, Bemis, J, Tse, JV, Huang, G, Park, J, Ji, C, Chen, J, Bemis, LT, Bunting, KD & Tse, W 2011, 'MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML', British journal of haematology, vol. 153, no. 6, pp. 753-757. https://doi.org/10.1111/j.1365-2141.2011.08662.x

@article{5254253df3174a0c92e558725727916c,

title = "MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML",

abstract = "MLLT11, an MLL fusion partner, is a poor prognostic biomarker for paediatric acute myeloid leukaemia (AML), adult normal cytogenetics AML, and adult myelodysplastic syndrome. MLLT11 is highly regulated during haematopoietic progenitor differentiation and development but its regulatory mechanisms have not been defined. In this study, we demonstrate by transfection experiments that MIR29B directly regulates MLLT11 expression in vitro. MIR29B expression level was also inversely related to MLLT11 expression in a cohort of 56 AML patients (P<0·05). AML patients with low MIR29B/elevated MLLT11 expression had poor overall survival (P=0·038). Therefore, MIR29B may be a potential prognostic biomarker for AML patients.",

keywords = "AML prognostic marker, AML survival, MIR29, MLL fusion gene, MLLT11",

author = "Yin Xiong and Zejuan Li and Min Ji and Tan, {Aik Choon} and Judson Bemis and Tse, {Jove Victor} and Gang Huang and Jino Park and Chunyan Ji and Jianjun Chen and Bemis, {Lynne T.} and Bunting, {Kevin D.} and William Tse",

year = "2011",

month = jun,

doi = "10.1111/j.1365-2141.2011.08662.x",

language = "English (US)",

volume = "153",

pages = "753--757",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML

AU - Xiong, Yin

AU - Li, Zejuan

AU - Ji, Min

AU - Tan, Aik Choon

AU - Bemis, Judson

AU - Tse, Jove Victor

AU - Huang, Gang

AU - Park, Jino

AU - Ji, Chunyan

AU - Chen, Jianjun

AU - Bemis, Lynne T.

AU - Bunting, Kevin D.

AU - Tse, William

PY - 2011/6

Y1 - 2011/6

N2 - MLLT11, an MLL fusion partner, is a poor prognostic biomarker for paediatric acute myeloid leukaemia (AML), adult normal cytogenetics AML, and adult myelodysplastic syndrome. MLLT11 is highly regulated during haematopoietic progenitor differentiation and development but its regulatory mechanisms have not been defined. In this study, we demonstrate by transfection experiments that MIR29B directly regulates MLLT11 expression in vitro. MIR29B expression level was also inversely related to MLLT11 expression in a cohort of 56 AML patients (P<0·05). AML patients with low MIR29B/elevated MLLT11 expression had poor overall survival (P=0·038). Therefore, MIR29B may be a potential prognostic biomarker for AML patients.

AB - MLLT11, an MLL fusion partner, is a poor prognostic biomarker for paediatric acute myeloid leukaemia (AML), adult normal cytogenetics AML, and adult myelodysplastic syndrome. MLLT11 is highly regulated during haematopoietic progenitor differentiation and development but its regulatory mechanisms have not been defined. In this study, we demonstrate by transfection experiments that MIR29B directly regulates MLLT11 expression in vitro. MIR29B expression level was also inversely related to MLLT11 expression in a cohort of 56 AML patients (P<0·05). AML patients with low MIR29B/elevated MLLT11 expression had poor overall survival (P=0·038). Therefore, MIR29B may be a potential prognostic biomarker for AML patients.

KW - AML prognostic marker

KW - AML survival

KW - MIR29

KW - MLL fusion gene

KW - MLLT11

UR - http://www.scopus.com/inward/record.url?scp=79957554543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957554543&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2011.08662.x

DO - 10.1111/j.1365-2141.2011.08662.x

M3 - Article

C2 - 21496004

AN - SCOPUS:79957554543

SN - 0007-1048

VL - 153

SP - 753

EP - 757

JO - British journal of haematology

JF - British journal of haematology

IS - 6

ER -

MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML

Abstract

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this